Nivolumab with chemotherapy as neoadjuvant treatment for inflammatory breast cancer. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text ...

Although all authors completed the disclosure declaration, the following author (s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article.

Informative censoring in a progression-free survival (PFS) analysis arises when patients are censored for initiation of an effective anticancer treatment before the protocol-defined progression, and ...

Glioblastoma (GBM) is a rare tumor and one of the most challenging malignancies to treat in all of oncology. Although advances have been made in the treatment of GBM, encouraging outcomes typically ...

Evaluation of real-world cost savings and utilization of biosimilar drugs in a community-based oncology practice. This is an ASCO Meeting Abstract from the 2021 ASCO Quality Care Symposium. This ...

Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancers. It is a heterogeneous disease, not only on the molecular level, but also on the pathologic and clinical levels. TNBC is ...

View all available purchase options and get full access to this article. The following represents disclosure information provided by authors of this manuscript. All relationships are considered ...

Recommendations of the American Society of Clinical Oncology VTE Guideline Panel include (1) all hospitalized cancer patients should be considered for VTE prophylaxis with anticoagulants in the ...

Two hundred twenty-nine chemotherapy-naive patients with advanced-stage NSCLC were enrolled onto a phase II selection trial evaluating sequential or concurrent chemotherapy (paclitaxel plus ...

This prospective, multicenter, multinational study was conducted in 14 medical practices on cancer patients undergoing either HEC or MEC treatment. Patients recorded episodes of nausea and vomiting in ...

First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers. This is an ASCO Meeting ...

Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia Salvage treatment consisted of two cycles of ...